Alx Oncology Holdings (ALXO)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from ALXO's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Alx Oncology Holdings's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Net income | -$83M | -$123M | -$161M | -$135M | -$102M |
| Free cash flow | -$69M | -$91M | -$132M | -$122M | -$84M |
| EPS (diluted) | -$2.07 | -$3.03 | -$3.74 | -$2.58 | -$1.90 |
| Operating margin | — | — | — | — | — |
Superinvestors who own ALXO
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Alx Oncology Holdings's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 2, 2026 | Corey S Goodman |
3,184,713 | $1.57 | $5M |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ALXO trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Alx Oncology Holdings insiders buying the stock?
1 open-market insider purchase of ALXO in the last 12 months, from SEC Form 4 filings.
Companies like Alx Oncology Holdings
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.